GlassScriptPhysician profile
Ana C Basso
NPI 1023096377
$4,683.95
in general payments reported to CMS, 2019-2025
34 companies · $608 in 2025
The $608 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $252 · 2021: $500 · 2022: $843 · 2023: $907 · 2024: $765 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Education: $83.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.87 |
| Education | $83.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.85 | 2019-2025 | Lo Loestrin Fe |
| Daiichi Sankyo INC. | $587.50 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $508.38 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $316.71 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $270.42 | 2023-2025 | Myfembree |
| Organon LLC | $239.54 | 2021-2024 | Nexplanon, Nuvaring |
| Bayer Healthcare Pharmaceuticals INC. | $228.65 | 2019-2025 | |
| Exeltis, USA INC. | $199.01 | 2020-2025 | Slynd |
| Myovant Sciences INC. | $198.51 | 2021-2022 | |
| Pfizer INC. | $189.58 | 2019-2024 | |
| Lupin INC. | $153.97 | 2019-2020 | |
| Biogen, INC. | $94.15 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $74.61 | 2019-2021 | |
| Millicent US INC | $73.49 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Amag Pharmaceuticals, INC. | $68.69 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.84 | 2019-2024 | Gardasil 9, Gardasil |
| Agile Therapeutics, INC. | $62.30 | 2021-2022 | |
| Hologic Sales and Service, LLC | $59.98 | 2019-2024 | Aptima |
| Coopersurgical, INC. | $43.59 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $31.67 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $31.49 | 2023 | Vivjoa |
| Scynexis, INC. | $30.32 | 2022 | |
| Minerva Surgical, INC | $30.09 | 2022-2025 | |
| Channel Medsystems, INC. | $27.95 | 2023-2024 | |
| Smith+Nephew, INC. | $27.52 | 2019 | |
| Aspira Women'S Health INC | $25.65 | 2024 | Ova1 |
| Evofem Biosciences, INC. | $19.52 | 2021 | |
| Teleflex LLC | $17.73 | 2019 | |
| Duchesnay USA Incorporated | $17.51 | 2019 | |
| Convatec INC. | $15.29 | 2024 | |
| Vertical Pharmaceuticals, LLC | $15.28 | 2019 | |
| Dysis Medical, INC. | $13.66 | 2022 | |
| Avion Pharmaceuticals | $13.20 | 2022 | |
| Olympus America INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Basso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.